Eboselume Akhuemonkhan1, Alyssa Parian1, Kathryn A Carson2, Susan Hutfless1,2. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
Background: Anemia is a frequent complication of Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD). Intravenous (IV) iron is recommended as the initial therapy for patients with clinically active IBD, severe anemia, and intolerance to oral iron. IV iron is associated with serious adverse effects including a black box warning for anaphylaxis with iron dextran and ferumoxytol. We aimed to examine the occurrence of adverse reactions including anaphylaxis after IV iron infusions in a large database of US IBD patients. Methods: We performed a retrospective analysis for encounters occurring between 2010 and 2014 in MarketScan, a US commercial claims database. We assessed the following adverse events: anaphylactic shock, bronchospasm, and hypotension among IBD patients receiving ferumoxytol, iron dextran, ferric gluconate, iron sucrose, and ferric carboxymaltose. We calculated the adverse event rate per 1000 infusions within 7 days of IV iron infusion. Results: In our study cohort of 6151 IBD patients (38.4% UC), 37 168 IV iron infusions were given (median, 3 infusions). There were very few adverse events; only 1.3% of IBD patients experienced any adverse reaction. The incident rate per 1000 infusions for any adverse event among IBD patients was highest among those receiving ferumoxytol (2.54, 95% confidence interval [CI], 1.26-5.11), ferric gluconate (1.85; 95% CI, 1.03-3.35), iron sucrose (1.74; 95% CI, 1.09-2.78), and iron dextran (0.96; 95% CI, 0.43-2.13). There were 0.24 anaphylactic shock events per 1000 IV iron infusions. Conclusions: About 1.3 of 100 IBD patients ever developed any adverse event. Because adverse reactions are rare, physicians should be encouraged to adhere to recommended guidelines for iron replacement among anemic IBD patients. 10.1093/ibd/izy063_video1izy063.video15768853346001.
Background: Anemia is a frequent complication of Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD). Intravenous (IV) iron is recommended as the initial therapy for patients with clinically active IBD, severe anemia, and intolerance to oral iron. IV iron is associated with serious adverse effects including a black box warning for anaphylaxis with iron dextran and ferumoxytol. We aimed to examine the occurrence of adverse reactions including anaphylaxis after IV iron infusions in a large database of US IBDpatients. Methods: We performed a retrospective analysis for encounters occurring between 2010 and 2014 in MarketScan, a US commercial claims database. We assessed the following adverse events: anaphylactic shock, bronchospasm, and hypotension among IBDpatients receiving ferumoxytol, iron dextran, ferric gluconate, iron sucrose, and ferric carboxymaltose. We calculated the adverse event rate per 1000 infusions within 7 days of IV iron infusion. Results: In our study cohort of 6151 IBDpatients (38.4% UC), 37 168 IV iron infusions were given (median, 3 infusions). There were very few adverse events; only 1.3% of IBDpatients experienced any adverse reaction. The incident rate per 1000 infusions for any adverse event among IBDpatients was highest among those receiving ferumoxytol (2.54, 95% confidence interval [CI], 1.26-5.11), ferric gluconate (1.85; 95% CI, 1.03-3.35), iron sucrose (1.74; 95% CI, 1.09-2.78), and iron dextran (0.96; 95% CI, 0.43-2.13). There were 0.24 anaphylactic shock events per 1000 IV iron infusions. Conclusions: About 1.3 of 100 IBDpatients ever developed any adverse event. Because adverse reactions are rare, physicians should be encouraged to adhere to recommended guidelines for iron replacement among anemic IBDpatients. 10.1093/ibd/izy063_video1izy063.video15768853346001.
Authors: Michael Auerbach; Jennifer A Pappadakis; Huzefa Bahrain; Sarah A Auerbach; Harold Ballard; Naomi V Dahl Journal: Am J Hematol Date: 2011-08-29 Impact factor: 10.047
Authors: Natalie Filmann; Julia Rey; Sven Schneeweiss; Sandro Ardizzone; Palle Bager; Gaetano Bergamaschi; Ioannis Koutroubakis; Stefan Lindgren; Felipe de la Morena; Bjørn Moum; Stephan R Vavricka; Oliver Schröder; Eva Herrmann; Irina Blumenstein Journal: Inflamm Bowel Dis Date: 2014-05 Impact factor: 5.325
Authors: C W Lees; A I Ali; A I Thompson; G-T Ho; R O Forsythe; L Marquez; C J Cochrane; S Aitken; J Fennell; P Rogers; A G Shand; I D Penman; K R Palmer; D C Wilson; I D R Arnott; J Satsangi Journal: Aliment Pharmacol Ther Date: 2009-02-01 Impact factor: 8.171
Authors: Asad H Arastu; Benjamin K Elstrott; Kylee L Martens; Jonathan L Cohen; Michael H Oakes; Zhoe T Rub; Joseph J Aslan; Thomas G DeLoughery; Joseph Shatzel Journal: JAMA Netw Open Date: 2022-03-01